Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

Mueck W, Kubitza D, Becka M.

Br J Clin Pharmacol. 2013 Sep;76(3):455-66. doi: 10.1111/bcp.12075.

2.

Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?

Hellwig T, Gulseth M.

Ann Pharmacother. 2013 Nov;47(11):1478-87. doi: 10.1177/1060028013504741. Epub 2013 Oct 9. Review.

PMID:
24259602
3.

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Dresser GK, Spence JD, Bailey DG.

Clin Pharmacokinet. 2000 Jan;38(1):41-57. Review.

PMID:
10668858
4.

[Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].

Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I.

Farm Hosp. 2009 May-Jun;33(3):125-33. Spanish.

PMID:
19712596
5.

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.

Moore KT, Vaidyanathan S, Natarajan J, Ariyawansa J, Haskell L, Turner KC.

J Clin Pharmacol. 2014 Dec;54(12):1407-20. doi: 10.1002/jcph.352. Epub 2014 Jul 3.

6.

Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.

Gong IY, Mansell SE, Kim RB.

Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70. doi: 10.1111/bcpt.12005. Epub 2012 Oct 11.

7.

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, Zhang D, Yu Z, Dias C, Shenker A, LaCreta F.

Br J Clin Pharmacol. 2015 May;79(5):838-46. doi: 10.1111/bcp.12541.

8.

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.

Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, McLeod J.

Clin Ther. 2009 Feb;31(2):286-98. doi: 10.1016/j.clinthera.2009.02.022.

PMID:
19302901
9.

Pharmacodynamic and pharmacokinetic basics of rivaroxaban.

Kreutz R.

Fundam Clin Pharmacol. 2012 Feb;26(1):27-32. doi: 10.1111/j.1472-8206.2011.00981.x. Epub 2011 Aug 16. Review.

PMID:
21848931
10.

Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR.

Curr Med Res Opin. 2008 Feb;24(2):591-9. doi: 10.1185/030079908X260871 .

PMID:
18205997
11.

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL.

Clin Pharmacokinet. 2005;44(3):279-304. Review.

PMID:
15762770
12.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.

Clin Pharmacol Ther. 2005 Dec;78(6):605-18.

PMID:
16338276
13.

Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.

Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW.

Chem Res Toxicol. 2001 Dec;14(12):1596-603.

PMID:
11743742
14.

Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.

Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE.

J Clin Pharmacol. 2003 Aug;43(8):831-9.

PMID:
12953340
16.

Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

Noh YH, Lim HS, Jin SJ, Kim MJ, Kim YH, Sung HR, Choi HY, Bae KS.

Clin Ther. 2012 May;34(5):1182-94. doi: 10.1016/j.clinthera.2012.04.001. Epub 2012 Apr 24.

PMID:
22534255
17.

CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.

Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C.

Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):45-54. doi: 10.1007/s13318-014-0235-4. Epub 2014 Nov 6.

PMID:
25374256
18.

Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.

Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT.

Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.

19.
20.

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, Berglund EG, Pang KS, Rahman A, Zhang L, Lesko LJ, Huang SM.

Biopharm Drug Dispos. 2012 Mar;33(2):99-110. doi: 10.1002/bdd.1771. Epub 2012 Mar 4.

PMID:
22270945

Supplemental Content

Support Center